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Epigenetic reprogramming of adult human somatic cells to alternative fates, such as the conversion of human
skin fibroblasts to induced pluripotency stem cells (iPSC), has enabled the generation of novel cellular
models of CNS disorders. Cell reprogramming models appear particularly promising in the context of human
neurological disorders of aging such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic
lateral sclerosis (ALS), for which animal models may not recapitulate key aspects of disease pathology. In
addition, recent developments in reprogramming technology have allowed for more selective cell fate inter-
conversion events, as from skin fibroblasts directly to diverse induced neuron (iN) subtypes. Challenges to
human reprogramming-based cell models of disease are the heterogeneity of the human population and
the extended temporal course of these disorders. A major goal is the accurate modeling of common nonfa-
milial ‘‘sporadic’’ forms of brain disorders.Introduction
The architectural complexity and cellular diversity of the
mammalian brain represent major challenges to the pursuit of
etiological factors that underlie human degenerative brain disor-
ders. A further impediment particular to the analysis of degener-
ative brain diseases is their protracted time course. And although
animal models have greatly informed current views on these dis-
orders, they have often failed to recapitulate key aspects of the
diseases. Thus, reductionist in vitro approaches using human
cells, such as the analysis of patient-derived neurons generated
using iPSC, have been met with particular excitement (Abelio-
vich and Doege, 2009; Takahashi and Yamanaka, 2006; Yama-
naka, 2007). More recent advances offer a variety of additional
tools, such as for the genetic correction of disease-associated
mutations in patient-derived cultures. Even with such advances,
cell-based approaches to study human neurodegenerative dis-
eases are limited by the inherent genetic diversity of the human
population, as well as technical variation among accessible
human tissue samples. Recent studies using human reprogram-
ming-based cell models of neuronal disorders have brought a
number of mechanistic topics to the fore, including the signifi-
cance of non-neuronal or non-cell-autonomous factors in dis-
ease, the relevance of epigenetic mechanisms, and the potential
of cell-based drug discovery approaches.
Cell-Fate Plasticity and iPSC Reprogramming
Pioneering studies in Shinya Yamanaka’s laboratory established
that a cocktail of four pluripotency factors—OCT4, SOX2, KLF4,
and c-MYC (OSKM), encoded in viral expression vectors—could
effectively reprogram skin fibroblasts to a pluripotent cell fate
within a fewweeks (Takahashi and Yamanaka, 2006; Yamanaka,
2007; Figure 1). Although iPSC may not precisely replicate the
epigenetic state of embryonic stem cells (ESC) (Kim et al.,2010), they functionally recapitulate key ESC attributes, such
as the seemingly unlimited ability to self-renew, as well as the
capacity to differentiate into a broad spectrum of somatic cell
fates. An early concern of the iPSC methodology was that
random insertion of the lentivirus vectors into the host genome
might adversely impact cells, leading to untoward phenotypic
changes such as tumor transformation. Alternative methods for
gene transduction, including the use of nonintegrating viral
vectors such as Sendai virus (Ban et al., 2011), episomal vectors
(Okita et al., 2011), protein transduction (Kim et al., 2009), or
transfection of modified mRNA transcripts (Warren et al.,
2010), have now been developed to mitigate such concerns.
These technologies are relevant both in the context of any future
clinical applications of iPSC as transplantable replacement cell
therapies, and as reductionist in vitro model systems in which
to pursue and validate therapeutic approaches for CNS disor-
ders. The latter application has advanced significantly since
the initial description of iPSC by the Yamanaka group (Takahashi
et al., 2007).
iPSC can be efficiently differentiated into a variety of neuronal
or nonneuronal fates, using a growing toolbox of differentiation
protocols. These protocols often take advantage of existing
knowledge about in vivo pathways that drive mammalian CNS
embryonic development. For example, Studer and colleagues
(Fasano et al., 2010; Kriks et al., 2011) described the efficient
production of multipotent neural stem cells with a ventral floor
plate phenotype—as defined by a transcription factor expres-
sion profile and competence in the generation of several ventral
floor-plate derived cell fates. The protocol is based on concur-
rent inhibition of two parallel SMAD/transforming growth
factor-b (TGFb) superfamily signaling pathways—mediated by
bone morphogenic proteins (BMP) and Activin/Nodal/TGFb
(Mun˜oz-Sanjua´n and Brivanlou, 2002). As these signalingNeuron 78, June 19, 2013 ª2013 Elsevier Inc. 957
Figure 1. Schematic of Reprogramming-
Based Approaches for the Generation of
Human Neuron Models of Disease
These approaches include the generation of iPSC
that are then differentiated to mature neurons,
directed conversion to induced neurons or
directed conversion to dividing neural progenitors,
that can give rise to mature CNS cell types.
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or mesoderm during CNS development, their concurrent inhibi-
tion promotes a ‘‘default’’ neural progenitor fate, which resem-
bles tripotent neural stem cells. Subsequent differentiation of
these neuronal stem cells toward selected mature neuronal
types can be achieved by inducing yet other signaling pathways
(Chambers et al., 2009, 2012; Kriks et al., 2011). For instance, a
mature midbrain dopaminergic neuron fate can be instructed by
Wnt, Sonic hedgehog (SHH), and FGF8 signaling pathway
induction, using chemical compounds or endogenous ligands.
Similar approaches have been described for the efficient pro-
duction of other neuronal fates, such as glutamatergic telence-
phalic forebrain neurons (Kirkeby et al., 2012), limb-innervating
motor neurons (Amoroso et al., 2013), and neural crest deriva-
tives (Chambers et al., 2009; Greber et al., 2011; Lee et al.,
2007; Table 1).
Some limitations to iPSC technology have emerged. Although
iPSC appear phenotypically stable through many cell divisions,
consistent with the self-renewal properties of stem cells, careful
inspection of the genomic DNA from iPSC has revealed a pro-
pensity toward the accumulation of genomic aberrations with
extended culturing (as well as the selection of any existing muta-
tions in skin fibroblasts that may confer a clonal growth advan-
tage) (Gore et al., 2011; Hussein et al., 2011; Laurent et al.,
2011). An additional issue with human iPSC technology has
been the lack of a standardized and practical method to
authenticate pluripotency (in contrast to rodent iPSC, which
can be authenticated for pluripotency by germline transmission).
A common approach has been the generation of teratomas—958 Neuron 78, June 19, 2013 ª2013 Elsevier Inc.tumors which harbor a broad variety of
cell types—upon transplantation of iPSC
into rodent tissue in vivo. However, this
method is cumbersome, particularly for
studies that necessitate the generation
of large cohorts of independent iPSC
clones, and can be misleading—even
aneuploidy cultures are competent at
the formation of teratomas. An alternative
approach to assess pluripotency poten-
tial is through gene expression and epige-
netic marker analyses, which appear
predictive (Bock et al., 2011; Stadtfeld
et al., 2010, 2012). An added layer of
complexity is that individual iPSC
clones—even within the same reprog-
ramming culture dish—may show signifi-
cant phenotypic variability, due either to
the acquisition of new genomicmutationsas above, or to the epigenetic heterogeneity, which remains
poorly understood (Gore et al., 2011; Hussein et al., 2011; Lau-
rent et al., 2011).
Directed Reprogramming: A Shortcut
The success of iPSC reprogramming has informed the pursuit of
other forms of somatic cell-fate conversion, such as directed
conversion from skin fibroblasts to forebrain neurons, termed
induced neurons (iNs) (Ambasudhan et al., 2011; Caiazzo
et al., 2011; Chatrchyan et al., 2011; Pang et al., 2011; Pfisterer
et al., 2011; Qiang et al., 2011; Vierbuchen et al., 2010; Yoo et al.,
2011). Directed conversion methods have taken essentially the
same conceptual strategy as with iPSC generation but are based
on the transduction of an empirically determined ‘‘cocktail’’ of
candidate neurogenic factors, rather than pluripotency factors.
A factor common to most of the directed conversion protocols
is ASCL1 (also termed MASH1), a basic helix-loop-helix (bHLH)
proneural gene that is required for the generation of neural pro-
genitors during embryogenesis and in the adult (Casarosa
et al., 1999; Nieto et al., 2001; Parras et al., 2002; Ross et al.,
2003), as well as for subsequent specification of some mature
neuronal subtypes (Lo et al., 2002). Additional conversion factors
may primarily impact on the neuronal subtype generated, akin to
the role of ‘‘terminal selector’’ factors during in vivo development
(Hobert, 2008). For instance, generation of rodent iN cells with a
forebrain glutamatergic phenotype was initially described using
an ASCL1/MYT1L/BRN2 cocktail (Vierbuchen et al., 2010).
Such iN conversions in rodent and human (hiN) cultures appears
qualitatively comparable (Pang et al., 2011; Qiang et al., 2011;





Reprogramming Efficiency Duration Reference






85% from hiPSC to
NPs; >60% from NP to
neurons
25 days to NPs with
additional 5 weeks to the
neuronal phenotype
Zeng et al., 2010
GABAergic neurons Low levels of SHH and
Wnts
87% 5–6 weeks Liu and Zhang, 2011
Cholinergic neurons High level of SHH and low
level of Wntsa, BMP9,
and NGF promote the
yield
14%–38% N/A Liu and Zhang, 2011;
Schnitzler et al., 2010
Dopaminergic neurons Noggin and SB431542
followed by SHH and
FGF8, then exposure




19 days Kriks et al., 2011
Motoneurons Noggin and SB431542




19 days Chambers et al., 2009
Serotoninergic neurons Matrigel and noggin
without EB formation or
additional factors.





GDNF, NT3, AA, cAMP
>90% from iPSCs to
NCSCs; 70%–85% from
NCSCs to neurons
15 days from hiPSC to
NCSCs; 12–14 days from
NCSCs to peripheral
neurons
Greber et al., 2011;
Menendez et al., 2013
Abbreviations: EB, embryonic body; NPs, neural progenitors; SHH, sonic hedgehog;Wnt, wingless-int; BMP, bonemorphogenetic protein; NGF, nerve
growth factor; FGF8, fibroblast growth factor 8; BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic factor; TGFb, transforming
growth factor b; cAMP, cyclic AMP; AA, ascorbic acid; RA, retinoic acid, GSK-3b, glycogen synthase kinase-3 b; NCSCs, neural crest stem cell.
aThe yield of cholinergic neurons is still very limited.
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sion efficiency appears generally lower in human cultures.
Directed reprogramming has been described toward spinal
motor neurons (iMN) (Son et al., 2011) and midbrain dopami-
nergic neuron (iDA) fates as well (Caiazzo et al., 2011; Kim
et al., 2011b; Pfisterer et al., 2011), using alternative neurogenic
regulatory cocktails (Table 2). At this time, directed conversion
does not offer as broad a selection of potential differentiated
cell fates as with iPSC differentiation protocols.
Directed conversion is operationally defined as a process that
does not follow a known mammalian neuronal developmental
pathway, nor the circuitous course of iPSC-derived neuron
generation through a pluripotent intermediate. Unlike iPSC gen-
eration, which is inefficient to the point that only a handful of
individual iPSC clones are typically obtained in a transduced
culture (0.1% of transduced cells are reprogrammed to plurip-
otency), a feature of the directed conversion methods is the
relatively higher efficiency (10% of cells may be converted)
(Qiang et al., 2011; Vierbuchen et al., 2010). Remaining cells
in iN cell cultures appear fibroblastic, and may be purified
away using fluorescent-activated cell sorting with neuronal
markers such as the neural cell adhesion molecule (NCAM)(Qiang et al., 2011). The higher efficiency of conversion
described with the iN approach obviates the need for clonal
expansion of individual reprogramming events; such cloning,
as in the context of iPSC generation, may theoretically bias sub-
sequent phenotypic analyses. iNs are postmitotic and display
typical neuronal morphological features and markers, as well
as active membrane properties of neurons (Pang et al., 2011;
Qiang et al., 2011; Vierbuchen et al., 2010; Yoo et al., 2011).
The iN conversion method appears robust in that nonfibroblas-
tic cell types, such as hepatocytes, also appear amenable to
hiN conversion (Marro et al., 2011). Directed in vitro conversion
offers some potential advantages over iPSC reprogramming
in the context of disease modeling. The relative simplicity of
the hiN methods—the process typically takes approximately
3–4 weeks and can be miniaturized to a multi-well format—
may enable the analysis of large patient cohorts without a
tremendous investment. However, as with iPSC reprogram-
ming, the process is highly dependent on the fidelity of the
source cells, such as skin fibroblasts.
Initial studies with neurons derived by directed conversion, in
rodent or human cultures, suggested functional immaturity
(Pang et al., 2011; Qiang et al., 2011; Vierbuchen et al., 2010;Neuron 78, June 19, 2013 ª2013 Elsevier Inc. 959
Table 2. A Summary of Directed Reprogramming Methods for the Generation of Human CNS Cell Phenotypes
Original
Cells Target Cells
Key Components for Differentiation or





Ascl1, Brn2, Myt1l, Oligo2, Zic1 9% 2–3 weeks Qiang et al., 2011
miR-9/9*, miR-124, Ascl1, Myt1l, NeuroD2 N/A 6 weeks Yoo et al., 2011
Ascl1, Brn2, Myt1l, NeuroD1 4% 2–5 weeks Pang et al., 2011
Ascl1, Brn2, Myt1l 4% 2 weeks Pfisterer et al., 2011
Brn2, Myt1l, miR-124 4%–11% 2–3 weeks Ambasudhan et al., 2011
Dopaminergic neurons Ascl1, LmX1a, Nurr1 3%–6% 2–3 weeks Caiazzo et al., 2011
Ascl1, Brn2, Myt1l, Lmx1a, FoxA2 5%–10% 3–4 weeks Pfisterer et al., 2011
Motoneurons Ascl1, Brn2, Myt1l, NeuroD1, Lhx3, Hb9,
lsl1, Ngn2
0.05% 4–5 weeks Chatrchyan et al., 2011
Neural stem cells Sox2 N/A 1–2 weeks Ring et al., 2012
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suggestive of functional synapses—was not readily apparent.
Addition of exogenous astrocytes, which are known to supply
essential factors for synaptogenesis in other primary neuron cul-
ture models (Eroglu and Barres, 2010; Ullian et al., 2004),
‘‘rescued’’ this phenotype. More recently, the issue of functional
maturity has also been addressed by altering the composition of
the neurogenic factor cocktail. For instance, transduction of a
cocktail of factors that includes miR-124—a highly expressed
neuronal microRNA that modulates expression of antineuronal
gene regulatory factors, such asREST, during CNSdevelopment
(Ambasudhan et al., 2011) —appeared effective in generating
mature neurons with evidence of spontaneous synaptic activity.
In a related approach, repression of poly-pyrimidine-tract bind-
ing protein (PTB), which is thought to normally oppose the action
of miR-124, appeared sufficient to convert fibroblasts to a
neuronal phenotype (Xue et al., 2013). Circumventing the need
for ASCL1 or other additional exogenous regulatory factors
significantly simplifies the conversion process.
Extrinsic cues also play a major regulatory role in the neuronal
fate conversion process. Withdrawal of serum, and inclusion of
neurotrophic factors, is a common feature in the directed reprog-
ramming protocols. Small molecule antagonists of glycogen
synthase kinase-3b (GSK-3b) and SMAD signaling—signaling
pathways implicated in CNS neurogenesis in vivo—have been
reported to significantly improve the efficiency of reprogramming
(Ladewig et al., 2012). Addition of exogenous primary astrocytes,
which likely provide essential factors for synaptic maturation
(Ullian et al., 2004), effectively promote synaptic activity in the
iN cultures (Pang et al., 2011; Qiang et al., 2011; Vierbuchen
et al., 2010; Yoo et al., 2011). A reduction in oxygen tension to
physiological levels (Davila et al., 2013) may also promote the
generation of mature neurons in vitro by directed conversion.
A particularly intriguing and potentially clinically relevant appli-
cation is the directed conversion of nonneuronal cells to neurons
in the adult CNS environment in vivo. In the adult mammalian
CNS, switching cell fates has appeared to be particularly
restricted, even from one neuronal type to another, although
such switching has been described during late development
(Rouaux and Arlotta, 2013). Genetic studies in the nematode
C. elegans have achieved the efficient in vivo directed conver-
sion of mature germ cells directly into neurons, by elimination960 Neuron 78, June 19, 2013 ª2013 Elsevier Inc.of chromatin regulatory factors (Tursun et al., 2011); it is unclear
whether such a strategy would promote directed fate intercon-
version in the adult mammalian CNS. Another drawback to the
directed generation of mature, postmitotic hiNs, is that these
cells cannot be further propagated. Thus for applications
requiring large cell numbers, the method necessitates an initial
amplification of the precursor fibroblasts.
An alternative, intermediate approach toward the generation
of new neurons is the directed conversion of skin fibroblasts to
a tripotent neural stem cell fate (Figure 1), termed induced neural
stem cells (iNSC). iNSC remain capable of cell division and differ-
entiation into a variety of CNS cell types (Han et al., 2012; Kim
et al., 2011a; Lujan et al., 2012; Ring et al., 2012; Thier et al.,
2012), including neurons, astrocytes, and oligodendrocytes.
Interestingly, the same set of OSKM pluripotency factors, as
described in the original iPSC protocol of the Yamanaka group,
appears sufficient for directed conversion to iNSC, depending
on the presence of iNSC permissive medium. Additional studies
indicate that transient, rather than sustained, OCT4 expression is
optimal for iNSC conversion (in contrast to iPSC generation)
(Thier et al., 2012), and furthermore that SOX2 alone appears suf-
ficient for the iNSC reprogramming process in some contexts
(Ring et al., 2012). The absence of expression of pluripotency
markers during iNSC reprogramming argues that the process
is truly ‘‘directed,’’ rather than simply an accelerated form of
the iPSC-mediated generation of neurons through a pluripotent
intermediate. Directed conversion to iNSC may prove particu-
larly applicable for CNS disease modeling, insofar as it may
marry the scalability of iPSC methods with the relative simplicity
of directed reprogramming.
Cell Reprogramming-Based Models of Adult
Neurological Disorders
A key promise of reprogramming-derived patient neurons for the
study of neurological disease is to achieve truly ‘‘personalized’’
medicine, as for identifying therapeutics that would be most
effective in a given patient (Figure 2). However, before such a
goal can be reached, informative disease-associated cell
models need to be validated. There is a growing list of neurolog-
ical disorders that have been pursued using reprogramming
technologies, primarily based on iPSC-derived patient neuron
cultures (Table 3). Although this review does not detail all studies,
Figure 2. Therapeutic Strategies and
Somatic Cell Reprogramming Technologies
‘‘Personalized medicine’’ approaches include the
generation of autologous ‘‘replacement’’ cells, as
well as the identification of therapeutics that are
particularly effective for a given individual.
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blasts from older individuals presents some technical hurdles
irrespective of the disease focus or the methodology. iPSC
and iN technologies have been successfully applied to human
cultures from older individuals, but efficiencies are typically
lower than in cultures from rodents, and validation more com-
plex. The basis for the lower reprogramming efficiency seen
with cells from older individuals is unclear, potentially relevant
to the age-associated nature of the diseases of interest. Age-
associated factors that impact reprogramming efficiency may
relate to the epigenetic state of the source somatic cells, the
accumulation of genetic mutations in the somatic cells, or alter-
ations in telomere length which have been reported to influence
reprogramming efficiency (Wang et al., 2012).
AD: Cell-Type-Specific In Vitro Correlates of Human
Brain Pathology
Given the slow progression of all of the neurodegenerative disor-
ders of aging, the notion that these could be modeled in a tissue
culture dish has been contentious. But there is accumulating
evidence that—despite the typical onset of these diseases late
in life—an underlying cellular or molecular pathological process
may persist throughout life, particularly in the context of familial
inherited disease mutations. This is illustrated in the context of
Alzheimer’s disease associated with familial mutations in prese-
nilin (PSEN)-1, PSEN-2, or amyloid precursor protein (APP; Israel
et al., 2012; Qiang et al., 2011).Mutations in these genes typically
cause early-onset forms of Alzheimer’s dementia with defects in
short-term memory and other realms of cognition, associated
pathologically with synaptic and neuronal loss, as well as amy-
loid plaques and neurofibrillary tangles, in selected brain regions
such as the medial temporal lobe. Studies with patient brain
tissue and animal models support a role for altered proteolytic
processing of APP to the amyloidogenic Ab42 fragment, relative
to the Ab40 fragment (De Strooper et al., 2012). At a molecularNeuronlevel, PSENs function within the g-secre-
tase proteolytic complex, and AD-associ-
ated familial mutations in PSENs, as well
as in APP, modify this intrinsic proteolytic
activity so as to increase the relative pro-
duction of the amyloidogenic Ab42 form.
However, mechanistic questions persist.
PSENs are implicated in the processing
of several dozen g-secretase substrates
other than APP, and in additional cellular
activities such as b-catenin signaling
and intracellular endosomal trafficking
(De Strooper et al., 2012); the relevance
of these functions to human disease
remains unclear. Furthermore, it remainsunresolved why clinical mutations in PSENs, which are ubiqui-
tously expressed, lead to a selective CNS neuronal degeneration
in AD patients. The amyloid hypothesis, that posits a primary role
for increased Ab as necessary and sufficient for AD (Hardy and
Selkoe, 2002), remains contentious, in part because therapeutic
strategies that specifically target only Ab have thus far met with
limited success in clinic trials.
At least five studies have now pursued hiN or iPSC-based
modeling strategies for AD (Israel et al., 2012; Kondo et al.,
2013; Qiang et al., 2011; Yagi et al., 2011; Yahata et al.,
2011). Directed conversion offers a particularly facile, albeit arti-
ficial, approach to pursue cell-type selectivity of a phenotype.
Surprisingly, conversion from skin fibroblasts to neurons was
found to modify the impact of PSEN mutations on APP process-
ing, in that the relative bias toward production of the pathogenic
Ab42 fragment (relative to Ab40) appeared magnified in
neurons. Why would cellular context impact an intrinsic PSEN
g-secretase activity? Further studies showed that PSEN mutant
FAD hiN cultures also displayed altered subcellular localization
of APP—toward enlarged endosomal compartments, relative
to hiNs from unaffected controls—whereas such redistribution
was not apparent in the source skin fibroblasts (Qiang et al.,
2011). Relocalization of APP away from the cell surface to endo-
somes is known to impact APP processing. A similar finding of
altered APP localization to endosomes was also described in
the context of iPSC-derived neurons from familial AD associ-
ated with a duplication of the APP locus (Israel et al., 2012).
Of note, the APP cellular relocalization phenotype is not simply
a secondary effect of increased Ab production, as pharmaco-
logical blockade of APP processing failed to suppress the
modified APP localization. Genetic ‘‘rescue’’ studies, in which
wild-type PSEN1 overexpressed in the PSEN1 mutant hiN cul-
tures suppressed the disease-associated phenotypes, support
a direct role for PSEN1 mutation in the phenotype of PSEN1
mutant cells, rather than a spurious effect due to unrelated78, June 19, 2013 ª2013 Elsevier Inc. 961
Table 3. Human Somatic Cell Reprogramming-Based Neuronal Models of Disease
Disease Genetic Defect Drug Testing Reference
Alzheimer’s disease Duplication of APP; Sporadic no Israel et al., 2012
PSEN1A246E; PSEN2N141I yes Yagi et al., 2011
APPE693D; APPV717L; Sporadic no Kondo et al., 2013
Parkinson’s disease a-synucleinA53T no Soldner et al., 2011
LRRK2G2019S yes Cooper et al., 2012; Nguyen et al., 2011;
Reinhardt et al., 2013; Sa´nchez-Dane´s
et al., 2012
PINK1Q456X; V170G yes Cooper et al., 2012; Seibler et al., 2011
Spinal muscular atrophy SMN exon7 deletion yesa Corti et al., 2012; Ebert et al., 2009
Familial amyotrophic lateral sclerosis SOD1L144F no Dimos et al., 2008
TDP-43Q343R; M337V; G298S yes Egawa et al., 2012
Huntington disease Htt 72 CAG repeats no An et al., 2012; Zhang et al., 2010
Familial dysautonomia IKBKAP exon20 skipping yes Lee and Studer, 2011
Rett syndrome MeCP2 mutations no Kim et al., 2011d; Marchetto et al., 2010; Xia
et al., 2012
Timothy syndrome CACNA1CG406R yes Pasxca et al., 2011
Gaucher disease GCaseN370S/84GG insertion no Mazzulli et al., 2011
Spinocerebellar Ataxia Type 2 ATXN2 (CAG) expansion no Xia et al., 2012
Schizophrenia Sporadic yes Brennand et al., 2011
Abbreviations: APP, amyloid precursor protein; PSEN, presenilin; LRRK2, leucine-rich repeat kinase 2; PINK1, PTEN-induced putative kinase 1; SMN,
survival of motor neuron protein; SOD1, superoxide dismutase 1; TDP-43, TAR DNA-binding protein-43; Htt, huntingtin; IKBKAP, inhibitor of kappa
light polypeptide gene enhancer in B cells, kinase complex-associated protein; MeCP2, methyl CpG binding protein 2; CACNA1C, a-1C subunit of
the L-type voltage-gated calcium channel; GCase, glucocerebrosidase; ATXN2, ataxin-2.
aOnly Ebert et al. performed the drug test.
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Reviewcommon variants that may be present in these cultures (Qiang
et al., 2011).
These initial studies with human neuron models of familial AD
supported the notion that processes other than extracellular Ab
fragment accumulation may play a role in AD pathology. To
further address this, Kondo et al. (2013) used human iPSC-
derived forebrain cortical neurons that harbor an APP muta-
tion, V717L, also associated with a familial clinical dementia
syndrome of the Alzheimer’s type, but one that appears to
lack the typical amyloid plaques, composed largely of extracel-
lular Ab42. iPSC-derived neurons from patients with the V717L
APP mutation showed reduced extracellular Ab42 and Ab40,
consistent with the CNS pathology in human patients with
this mutation. Interestingly, intracellular accumulation of Ab
forms was increased (Kondo et al., 2013), suggesting an alter-
native mechanism of pathology. The increase intracellular Ab
was correlated with markers of endoplasmic reticulum (ER)
and oxidative stress, as well as apoptosis, in the iPSC-derived
neuron cultures carrying the V717L mutation. Docosahexaenoic
acid (DHA), a therapeutic candidate for AD, relieved the ER
stress responses and suppressed apoptosis in the mutant
cells.
An additional pathological finding that typifies AD patient brain
is the accumulation of modified, hyperphosphorylated, and
aggregated TAU protein, leading to the accumulation of neu-
rofibrillary tangles. APP mutant human iPSC-derived neuron
cultures have been reported to harbor increased TAU phosphor-
ylation (Israel et al., 2012), whereas the majority of transgenic962 Neuron 78, June 19, 2013 ª2013 Elsevier Inc.rodent models fail to do so, likely reflecting species differences
in the TAU gene. Interestingly, inhibition of g-secretase—which
is required for Ab fragment generation—failed to suppress
such phospho-TAU pathology in iPSC-derived APP mutant neu-
rons, whereas inhibition of b-secretase function appeared effec-
tive (Israel et al., 2012). As inhibition of either secretase complex
suppresses Ab production, this finding further supported the
notion that aspects of APP biology other than extracellular Ab
accumulationmay play an important role in AD pathology. A cen-
tral remaining question is whether late-onset nonfamilial AD,
which represents the vast majority of cases, is associated with
similar cellular and molecular mechanisms. A preliminary anal-
ysis of iPSC-derived neuron cultures from two individuals with
common nonfamilial AD reported that one of these displayed
changes in APP processing akin to those seen in cultures with
familial mutations in APP, whereas the second did not show
such changes; these data underscore the apparent heterogene-
ity of common nonfamilial disease and the need for expanded
cohorts. Common genetic variants in the human population,
such as at the APOE and SORLA/SORL1 loci, significantly
impact sporadic AD risk (Bettens et al., 2013), and thus it will
be of interest to pursue the impact of such variants in reprogram-
ming-based human cell models of AD. For instance, as SORLA/
SORL1 is thought to play a role in the trafficking of APP to and
from intracellular endosomal compartments (Rogaeva et al.,
2007), it is tempting to consider the functional consequences
of human SORLA/SORL1 variants on APP processing in the
human reprogramming models.
Table 4. Technologies for the Correction (or Introduction) of Disease-Associated Mutations in Human Cell Models
Genomic Correction Method Applied Neurological Disorder Reference
Sequence-specific oligodeoxynucleotides mediated replacement Spinal muscular atrophy Corti et al., 2012
Zinc finger nuclease (ZFN)-mediated editing Parkinson’s disease Reinhardt et al., 2013; Soldner et al., 2011
Transcription activator-like effector nucleases (TALENs) mediated
editing
N/A Hockemeyer et al., 2011
Helper-dependent adenoviral vector (HDAdV)-mediated gene
editing
Parkinson’s disease Liu et al., 2012
Homologous arms from a bacterial artificial chromosome (BAC)
mediated homologous recombination
Huntington disease An et al., 2012
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Rodent genetic models of PD have often failed to recapitulate
key aspects of human disease pathology, such as the somewhat
selective midbrain dopaminergic neuron loss or accumulation of
intracellular aggregates of aSynuclein (aSyn) protein (Dawson
et al., 2010). This may simply reflect the lengthy of the time
course of the human disease, or species-specific aspects.
Also, environmental insults such as toxins have been hypothe-
sized to interact with genetic factors in the pathogenesis of
PD. Autosomal-dominant mutations in LRRK2, which encodes
a large multidomain kinase, represent the most common known
familial genetic cause of PD. LRRK2 mutant iPSC-derived neu-
rons from familial PD patients have been associated with
increased sensitivity to oxidative stress, such as in the form of
6-hydroxydopamine or 1-methyl-4-phenylpyridinium (MPP+)—
which selectively enter dopaminergic neurons through the dopa-
mine transporter—as well as hydrogen peroxide or rotenone
(Cooper et al., 2012; Nguyen et al., 2011; Reinhardt et al.,
2013). The increased sensitivity is associated with activation of
extracellular signaling-related kinases (ERKs), and inhibition of
this pathway ameliorated toxicity (Reinhardt et al., 2013). Simi-
larly, increased sensitivity to oxidative toxins has been
reported with iPSC-derived neurons that harbor PD-associated
homozygous recessive mutations in PINK1 (Cooper et al.,
2012), a mitochondrial kinase, or a familial inherited triplication
of the aSyn locus (Byers et al., 2011).
The tremendous genetic diversity across the human popula-
tion does raise the possibility that any given phenotype observed
in cultures from a unique individual may not be due to a particular
mutation or disease. To link mutations in PD genes to cell pheno-
types, an elegant approach is the precise genetic correction of
the lesion, as was described for a PD-associated aSynmissense
mutation using zinc finger nuclease (ZFN) technology (Soldner
et al., 2011). There are now several additional effective platforms
for genetic correction, summarized in Table 4. Transcription
activator-like effector (TALE) nucleases, like ZFNs, allow for the
precise correction (or induction) of genomic mutations, so as
to enable the subsequent phenotypic analysis of mutant cells
alongside isogenic ‘‘control’’ cultures (Ding et al., 2013; Hocke-
meyer et al., 2011; Soldner et al., 2011). Both technologies intro-
duce DNA nucleases that are fused to DNA-binding protein
elements, designed to generate double-stranded DNA breaks
at selected genomic sites. These DNA breaks promote homol-
ogous recombination with exogenous or endogenous DNA
sequences. A limitation with the ZNF and TALE nuclease tech-nologies is that they must be custom-engineered and empirically
tested for each desired site in the genome. A more recent
approach derived from prokaryotic adaptive immune defenses,
termed clustered regularly interspaced short palindromic re-
peats (CRISPR)/CRISPR-associated (Cas), enables RNA-guided
genomic editing, and is potentially simpler to design (Cong et al.,
2013; Mali et al., 2013); CRISPR remains unproven in the context
of cell-based disease models. Using yet another approach—
helper-dependent adenoviral vector (HDAdV) mediated gene
targeting—a recent study ‘‘corrected’’ PD-associated familial
mutations in LRRK2 in iPSC cultures, and thereby linked these
mutations with alterations in nuclear envelope structure (Liu
et al., 2012). It remains to be determined whether such nuclear
envelope changes are consistent findings in PD patient-derived
cultures.
Studies in human iPSC-derived neuronal models of PD have
also sought to reveal mechanistic details about PD etiology,
such as mitochondrial alterations (Jiang et al., 2012; Seibler
et al., 2011), and how thesemay lead to the pathological features
of the disease. iPSC-derived neurons with mutations in PINK1
have been reported to display mitochondrial function abnormal-
ities, defective mitochondrial quality control, and altered recruit-
ment to mitochondria of exogenously transduced PARKIN—a
ubiquitin ligase that is encoded by another familial PD gene
(Rakovic et al., 2013). Surprisingly, PARKIN-deficient iPSC-
derived neurons from familial PD patients did not appear to
show frank mitochondrial defects, suggesting potential redun-
dancy (Jiang et al., 2012). It remains unclear from these studies
why dopaminergic neurons are particularly vulnerable to muta-
tions in genes that appear widely expressed, but the iPSC-based
models are well-positioned to pursue that issue. One possibility
is that dopaminergic neurons are prone to a higher level of
intrinsic oxidative stress, which predisposes the cells to damage
in the context of PD familial genetic mutations.
In addition to mitochondrial pathology in PD, another promi-
nent feature is the accumulation of aSyn protein, which has
been noted to be increased in sporadic disease aswell as familial
forms. Heterozygous carriers of mutations in b-glucocerebrosi-
dase (GBA), which encodes an essential lysosomal degradation
machinery enzyme, are at increased risk of PD, and iPSC derived
neurons from such individuals have been reported to display a
dramatically increased accumulation of aSyn protein (Mazzulli
et al., 2011), as is seen in PD brain pathology. In the homozygous
state, GBA mutations are associated with Gaucher’s disease,
with severe lysosomal dysfunction typically early in life (MazzulliNeuron 78, June 19, 2013 ª2013 Elsevier Inc. 963
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triplication of the aSyn locus display similarly increased accumu-
lation of aSyn protein (Byers et al., 2011). Regulation of aSyn
gene expression is species specific, and appears to be modified
both in familial and sporadic PD brain (Rhinn et al., 2012); thus
in vitro human neuronal models may prove to be particularly
useful.
ALS and Nonautonomous Mechanisms of Disease
ALS is characterized by a progressive loss of motor neurons
in the spinal cord, leading to difficulty with movement and
breathing. Rare familial forms of ALS have been unambiguously
associated with mutations in superoxide dismutase-1 (SOD1),
transactive response DNA-binding 43 (TDP-43), fused in sar-
coma (FUS), C9orf72, and approximately a dozen other genes
(Ferraiuolo et al., 2011). A common theme in the context of
several of these familial forms—including mutant forms of
SOD1, TDP-43, FUS, and C9orf72—is the formation of cyto-
plasmic aggregates (Ash et al., 2013; Da Cruz and Cleveland,
2011; Mori et al., 2013). Furthermore, TDP-43 aggregates are
found in the majority of nonfamilial ‘‘sporadic’’ ALS cases even
in the absence of known mutations, supporting the idea that
common mechanisms underlie the familial and sporadic forms.
Cytoplasmic TDP-43 aggregates are typically seen in neurons
and astrocytes along with concurrent ‘‘clearing’’ of the normal
nuclear localization of TDP-43, and this has opened the possibil-
ity that loss of nuclear TDP-43 function, as well as aggregation,
may play a role in pathology.
Model organism studies, frommice to yeast, have brought sig-
nificant insight into the role of genes such as TDP-43 in vivo, but
questions persist about the specific mechanism of action in the
context of human motor neurons. For instance, the relative
importance of protein aggregates, nuclear clearing, and the
nonautonomous impact of astroglial pathology on motor neuron
loss (Da Cruz and Cleveland, 2011) is unclear. Initial analyses of
iPSC-derived spinal motor neurons with mutations in TDP-43
have reported evidence of reduced motor neuron survival
in vitro, particularly in the context of an oxidative toxin, arsenite,
and accumulation of TDP-43 (Bilican et al., 2012; Egawa et al.,
2012). A critical point is that these studies did not include valida-
tion using a ‘‘rescue’’ approach or cohorts of sufficient size for a
statistical analysis, both of which are essential. A cohort of iPSC-
derived motor neuron cultures that harbor ALS-associated
mutations in SOD1 has been generated (Boulting et al., 2011),
and phenotypic analysis with respect to disease-relevant pheno-
types will be of interest.
There is broad interest in the role of non-neuronal CNS cell
types, such as astrocytes (Lobsiger and Cleveland, 2007), oligo-
dendrocytes (Kang et al., 2013), and microglia (Boille´e and
Cleveland, 2008), in ALS pathology. This is based in part on path-
ological examination at autopsy, as well as on elegant rodent
studies that have dissected the impact of ALS-associated
mutant SOD1, when expressed selectively within different CNS
cell populations, on motor neuron loss (Lobsiger and Cleveland,
2007). Human or rodent ESC-derived motor neurons, (Di Giorgio
et al., 2008; Di Giorgio et al., 2007; Nagai et al., 2007), as well as
human iPSC-derived motor neurons (Serio et al., 2013), have
been reported to display reduced survival when co-cultured964 Neuron 78, June 19, 2013 ª2013 Elsevier Inc.with murine astrocytes that overexpress mutant SOD1 (as
compared to control astrocytes). The nature of the astrocytes
-derived factor has been speculated to be a secreted inflamma-
tory mediator (Lobsiger and Cleveland, 2007); an alternative and
intriguing concept is that the factor may represent extracellular
propagation of the mutant SOD1 protein itself (Pimplikar et al.,
2010). A role for astrocytes in ALS pathology has also been
considered with respect to TDP-43 mutations (Serio et al.,
2013). Taken together, these studies are intriguing but require
further validation with additional cultures and using ‘‘rescue’’
approaches. The nonautonomous role of astrocytes and other
cell types in CNS neurodegeneration is of interest beyond ALS
(Lobsiger and Cleveland, 2007; Polymenidou and Cleveland,
2011), in disorders such as with PD, AD, and frontotemporal
dementia (FTD). In vitro coculture approaches offer a reduc-
tionist model system to address this mechanism.
Therapeutics: The Endgame
Human reprogramming-based neuronal models offer the poten-
tial of ‘‘personalized medicine’’ strategies for adult CNS disor-
ders, wherein neurons from a particular patient would be used
to optimize an individualized therapeutic approach. Beyond
that, human cells may complement limitations of animal models.
A major disappointment over the past decade has been the lack
of significant efficacy—in human clinical trials for AD, PD, and
ALS—of a host of candidate drugs that had previously appeared
potent in animal models. For instance g-secretase inhibitors,
such as semagacestat, are highly effective in transgenic models
of AD, but failed in human studies (Karran et al., 2011). This may
reflect species differences between mouse and man, or the
apparently distinct activity of this compound in the context of
high levels of APP substrate, as in transgenic mice. Alternatively,
it may be that suppressing APP processing to Abmay not be suf-
ficient to prevent neurodegeneration in AD, if other defects—
such as the alterations in endosomal compartments reported
in reprogramming-based cell models (Israel et al., 2012; Qiang
et al., 2011)—play a significant role.
Therapeutic studies in reprogramming models have typically
used candidate approaches to validate or test selected com-
pounds. In a panel of iPSC-derived dopamine neurons from
PD patients with mutations in either LRRK2 or PINK1, the kinase
inhibitor GW5074 was reported to protect cultures from the
toxicity of valinomycin (a potassium ionophore that induces
oxidative stress and thus may mimic environmental stressors
in vivo [Cooper et al., 2012]). In AD patient iPSC-derived cortical
neurons that harbor duplication of the APP locus, b-secretase
but not g-secretase inhibitors were found to suppress an altered
TAU phosphorylation phenotype (Israel et al., 2012). A histone
acetyltransferase inhibitor, anacardic acid, was reported to be
protective in the context of TDP-43 mutant iPSC-derived motor
neurons treated with the neurotoxin arsenite (Egawa et al.,
2012); anacardic acid was chosen on the basis of its potential
tomodify gene expression changes observed in themutant cells.
It will be important to further validate these candidates therapeu-
tics in multiple independent cell cultures.
Phenotypic analyses of functional neuronal parameters—such
asmembrane excitability or synaptic connectivity—have thus far
been limited, in the context of reprogramming-based models of
Neuron
Reviewneurodegeneration. Recent studies using iPSC-derived neurons
in the context of psychiatric disorders, such as schizophrenia
(Brennand et al., 2011) and Timothy syndrome (Pasxca et al.,
2011; Yazawa and Dolmetsch, 2013), have considered such
functional neuronal parameters, and attempted to use these
analyses in the pursuit of therapeutics. In iPSC-derived cortical
neuron cultures from schizophrenia patients and unaffected
controls, synaptic connectivity was evaluated in terms of the
trans-synaptic spread of a modified, fluorescently tagged rabies
virus (Brennand et al., 2011). Such synaptic connectivity
appeared reduced in the schizophrenia patient iPSC-derived
neurons, relative to iPSC-derived neurons from unaffected indi-
viduals. Further studies are needed to determine whether this
observation can be generalized to independent patient cohorts
with schizophrenia, and with respect to its utility in screening
potential drugs (Brennand et al., 2011).
The different reprogramming-based neuronal models dis-
cussed above may have unique virtues or limitations in the
context of drug screens. iPSC-based models allow for extensive
expansion of cells, and thus may be beneficial in a broad high-
content screen. A method developed to further facilitate the
use of iPSC in high-content drug screens enables the expansion
and maintenance of iPSC-derived neural progenitors (Koch
et al., 2009; Li et al., 2011; Reinhardt et al., 2013). In contrast
to iPSC technology, high-content screening with direct reprog-
ramming-based models requires expansion of the source fibro-
blast cultures, which is limited by senescence. The use of iNSC
technology, as detailed above, may combine the advantages of
these two approaches. Finally, reprogramming-derived neurons
have been pursued as autologous ‘‘replacement’’ cell therapies,
as has been reviewed elsewhere (Nakamura et al., 2012).
Epigenetic Reprogramming and the Etiology of
Neurological Disorders: Nature versus Nurture
Reprogramming technologies, such as iPSC or iN generation,
theoretically ‘‘erase’’ the existing epigenetic state of a cell and
establish an alternative state. Such epigenetic states are deter-
mined in part by direct modifications of genomic DNA, including
methylation or hydroxymethylation, aswell as by binding of chro-
matin factors such as histones that modify the accessibility of
genomic DNA (Tomazou and Meissner, 2010). Yet other regula-
tors, that include both protein and non-coding RNA factors,
serve to refine the epigenetic state of individual genetic loci.
Additionally, the three-dimensional structure of chromatin,
determined by yet poorly defined nuclear elements, may broadly
impact the epigenetic program.
In the context of patient-derived cultures, historical events of
potential relevance to disease—such as aging or toxin expo-
sure—may theoretically underlie a persistent change in epige-
netic state, and this may in turn impact cellular phenotypes.
The cell-type-specific epigenetic state of a starting cell—in
contrast to genetic factors—is predicted to be ‘‘erased’’ in the
context of somatic cell reprogramming. Thus, epigenetic reprog-
ramming models, such as patient iPSC-derived neurons, may
not display a given disease phenotype, if it is epigenetic in origin.
Conversely, a disease-associated phenotype that is apparent in
reprogramming-derived cell models is predicted to be genetic in
origin. A caveat is that reprogramming has often appearedincomplete: ‘‘epigenetic memory’’ persists in iPSC-derived cul-
tures as to their cells of origin (Kim et al., 2010, 2011c) as well
as with directed reprogramming (Khachatryan et al., 2011).
Going forward, it will be of high interest to directly assess
epigenetic changes associated with disease states in reprog-
rammed neuron models. In some contexts, ‘‘incomplete reprog-
ramming—which retains significant epigenetic memory—may
be desirable. More speculatively, directed reprogramming to
neurons may present an advantage over iPSC reprogramming
followed by differentiation; single step reprogramming to neu-
rons is perhaps more likely to retain epigenetic memory of prior
events, leading to disease-related cellular phenotypes. How-
ever, epigenetic memory in skin cells may not be relevant to
CNS disorders.
Conclusion
In summary, the application of reprogramming technologies
toward the generation of accurate and simple human cell models
of adult neurological disorders is a promising approach. It is
perhaps unexpected that diseases of aging such as familial
Alzheimer’s disease would be recapitulated to some extent ‘‘in
a dish.’’ This reflects an emerging theme, in which underlying
molecular and cellular culprits to these diseases of aging may
often be present throughout life, whereas unknown ‘‘second
hits’’ ultimately lead to the full expression of disease. Cell models
may allow for the identification of extrinsic factors that promote
the expression of disease phenotypes, as well as ones that sup-
press such expression.
Reprogramming-based cell models afford a valuable potential
approach to the investigation of adult neurological disorders.
Although this review focuses on AD, PD, and ALS, many other
neurological disorders—such as FTD (Almeida et al., 2012) or
susceptibility to herpes simplex virus-I encephalopathy (Lafaille
et al., 2012)—are amenable to these approaches. A particularly
exciting direction is the application of this technology to the
study of non-familial disease, and risk-associated variants. The
advent of affordable whole-genome sequencing, as well as large
scale genome-wide association studies, are particularly timely in
this regard. Amajor hurdle to the interpretation of human reprog-
ramming-based disease models is the inherent variation among
samples, due both to genetic diversity as well as the distinct per-
sonal histories that may lead to epigenetic diversity. It will be
essential to use patient and control cohorts (of independent cul-
tures) that are sufficiently large to enable statistically meaningful
analyses, which has often not been the case in ‘‘first-generation’’
models. Furthermore, going forward, studies that lack a genetic
or biochemical complementation approach to directly link a
given genetic variant (or mutation) a phenotype must be treated
with some skepticism.
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